RITA 3 Trial Summary Background: Methods: Findings: Interpretation: Key Takeaways: Source
NSTEMI
POPular AGE Trial Summary: Antiplatelet agent in NSTEMI
2020 POPULAR AGE TRIAL Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome multicenter, randomized controlled trial Objective: To evaluate the effectiveness of clopidogrel compared with ticagrelor or prasugrel among patients ≥70 … Read More
Tags: ACS, clopidogrel, heart attack, NSTEMI, prasugrel, ticagrelor